Mammoth Biosciences operates as a privately held biotechnology enterprise co-founded by CRISPR pioneer Jennifer Doudna, focusing on next-generation CRISPR-based gene editing and diagnostic platforms. Because it is a private company funded through venture capital rounds and strategic partnerships rather than an initial public offering on major public exchanges, retail investors cannot buy shares directly on public stock markets. Its equity ownership remains restricted to institutional venture funds, founders, and strategic corporate backers.